[go: up one dir, main page]

GT201300196A - Moduladores del receptor de glucagón - Google Patents

Moduladores del receptor de glucagón

Info

Publication number
GT201300196A
GT201300196A GT201300196A GT201300196A GT201300196A GT 201300196 A GT201300196 A GT 201300196A GT 201300196 A GT201300196 A GT 201300196A GT 201300196 A GT201300196 A GT 201300196A GT 201300196 A GT201300196 A GT 201300196A
Authority
GT
Guatemala
Prior art keywords
compositions
glucagon
agonists
receiver modulators
modulators
Prior art date
Application number
GT201300196A
Other languages
English (en)
Inventor
Aspnes Gary Erik
Didiuk Mary Theresa
Filipski Kevin James
Guzman-Perez Angel
Lee Esther Cheng Yin
Pfefferkorn Jeffrey Allen
Stevens Benjamin Dawson
Tu Meihua Mike
Original Assignee
Nakagawa Takashi
Arkray Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nakagawa Takashi, Arkray Inc filed Critical Nakagawa Takashi
Publication of GT201300196A publication Critical patent/GT201300196A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS QUE SON ANTAGONISTAS, AGONISTAS/ANTAGONISTAS MIXTOS, AGONISTAS PARCIALES, MODULADORES ALOSTÉRICOS NEGATIVOS O AGONISTAS INVERSOS DEL RECEPTOR DE GLUCAGÓN, A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS Y A LOS USOS DE LOS COMPUESTOS O COMPOSICIONES.
GT201300196A 2011-02-08 2013-08-07 Moduladores del receptor de glucagón GT201300196A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161440578P 2011-02-08 2011-02-08
US201161441044P 2011-02-09 2011-02-09
US201261585834P 2012-01-12 2012-01-12

Publications (1)

Publication Number Publication Date
GT201300196A true GT201300196A (es) 2014-06-06

Family

ID=45607316

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300196A GT201300196A (es) 2011-02-08 2013-08-07 Moduladores del receptor de glucagón

Country Status (39)

Country Link
US (5) US8507533B2 (es)
EP (1) EP2673260B1 (es)
JP (1) JP5562495B2 (es)
KR (2) KR101585840B1 (es)
CN (2) CN104744370A (es)
AP (1) AP3338A (es)
AR (1) AR085149A1 (es)
AU (1) AU2012215114B2 (es)
BR (1) BR112013020035A2 (es)
CA (1) CA2825102C (es)
CL (1) CL2013002053A1 (es)
CO (1) CO6741217A2 (es)
CR (1) CR20130372A (es)
CY (1) CY1118039T1 (es)
DK (1) DK2673260T3 (es)
DO (1) DOP2013000181A (es)
EA (1) EA023517B1 (es)
EC (1) ECSP13012871A (es)
ES (1) ES2597972T3 (es)
GE (1) GEP20156351B (es)
GT (1) GT201300196A (es)
HK (1) HK1207858A1 (es)
HR (1) HRP20161177T1 (es)
HU (1) HUE030364T2 (es)
IL (1) IL227559A (es)
LT (1) LT2673260T (es)
ME (1) ME02502B (es)
MX (1) MX2013009140A (es)
NI (1) NI201300068A (es)
PE (1) PE20140253A1 (es)
PH (1) PH12013501557A1 (es)
PT (1) PT2673260T (es)
RS (1) RS55225B1 (es)
SG (1) SG192004A1 (es)
SI (1) SI2673260T1 (es)
TW (3) TW201540710A (es)
UY (1) UY33896A (es)
WO (1) WO2012107850A1 (es)
ZA (1) ZA201306310B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012107850A1 (en) * 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
US20120316182A1 (en) * 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013147026A1 (ja) 2012-03-29 2013-10-03 武田薬品工業株式会社 芳香環化合物
WO2014088983A1 (en) 2012-12-07 2014-06-12 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
CN105121411B (zh) 2013-04-15 2017-10-10 杜邦公司 杀真菌酰胺
CN107235960B (zh) * 2016-03-29 2021-01-29 浙江海正药业股份有限公司 酰胺类衍生物、其制备方法及其在医药上的用途
US11384060B2 (en) * 2017-01-24 2022-07-12 Alphala Co., Ltd. Amide compounds and use thereof
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
AU2018258274C1 (en) 2017-04-24 2021-12-02 Tesaro, Inc. Methods of manufacturing of niraparib
IL297413B2 (en) 2018-02-28 2024-07-01 Basf Se Use of alkoxypyrazoles as nitrification inhibitors
KR20210011934A (ko) * 2018-05-24 2021-02-02 바이엘 악티엔게젤샤프트 할로겐화된 n-아릴피라졸의 제조 방법
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
MX2022004390A (es) 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
US12358881B2 (en) * 2020-03-06 2025-07-15 Alphala Co., Ltd. Processes for producing amide compounds, and their crystalline and salt form
CN111793033A (zh) * 2020-08-10 2020-10-20 成都正善达生物医药科技有限公司 一种普那布林中间体咪唑甲醛类化合物的制备方法
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024186983A2 (en) * 2023-03-07 2024-09-12 The Board Of Trustees Of The University Of Illinois Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (ms) and other demyelinating, inflammatory and neurodegenerative diseases

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5320825A (en) 1991-05-01 1994-06-14 Trustees Of The University Of Pennsylvania Serotonin reuptake inhibitors for S.P.E.C.T. imaging
WO1994014427A2 (en) 1992-12-23 1994-07-07 Zymogenetics, Inc. Use of skyrin and analogues for the treatment of diabetes mellitus and process for their preparation
EP0617001B1 (en) 1993-03-19 2000-01-26 Merck & Co. Inc. Phenoxyphenylacetic acid derivatives
GB9408185D0 (en) 1994-04-25 1994-06-15 Fujisawa Pharmaceutical Co New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
DE4426346A1 (de) 1994-07-25 1996-02-01 Basf Ag Herbizide Pyrazinderivate
GB2292149A (en) 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
US5837719A (en) 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
JPH11514651A (ja) 1995-10-31 1999-12-14 メルク エンド カンパニー インコーポレーテッド 置換ピリジルピロール、前記化合物を含む組成物及び使用方法
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
US5880139A (en) 1996-11-20 1999-03-09 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
EP0959886A4 (en) 1996-11-20 2001-05-02 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS
AR038955A1 (es) 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
BR9713863A (pt) 1996-12-05 2000-03-14 Amgen Inc Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase
PL334059A1 (en) 1996-12-11 2000-01-31 Basf Ag Ketone benzamides useful as calpain inhibitors
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
JP2003514508A (ja) 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
WO1999032448A1 (en) 1997-12-19 1999-07-01 Amgen Inc. Substituted pyridine and pyridazine compounds and their pharmaceutical use
CA2371308A1 (en) 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands
RU2267484C2 (ru) 1999-04-28 2006-01-10 Авентис Фарма Дойчланд Гмбх Производные диариловой кислоты и фармацевтическая композиция на их основе
WO2000069810A1 (en) 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
CN1437581A (zh) 2000-06-23 2003-08-20 诺沃挪第克公司 胰高血糖素拮抗剂/反向激动剂
AU2002223502A1 (en) 2000-11-17 2002-05-27 Novo-Nordisk A/S Glucagon antagonist/inverse agonist
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
EA200300944A1 (ru) 2001-02-28 2004-04-29 Мерк Энд Ко., Инк. Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
EP1453541A1 (en) 2001-12-03 2004-09-08 Novo Nordisk A/S Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
EP1463715A1 (en) 2001-12-03 2004-10-06 Novo Nordisk A/S Novel glucagon antagonists
WO2003051357A1 (en) 2001-12-19 2003-06-26 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
US20030171411A1 (en) 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
TWI262917B (en) 2002-02-01 2006-10-01 Dainippon Sumitomo Pharma Co 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
CA2479338A1 (en) 2002-03-20 2003-10-02 Metabolex, Inc. Substituted phenylacetic acids
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
WO2004002480A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
US20060035958A1 (en) 2002-09-12 2006-02-16 Joseph Duffy Method of treating diabetes and related conditions
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
US20040097557A1 (en) 2002-11-13 2004-05-20 Duffy Joseph L. Cyanothiophene derivatives, compositions containing such compounds and methods of use
JP2006509015A (ja) 2002-12-04 2006-03-16 メルク　エンド　カムパニー　インコーポレーテッド スピロ環尿素、そのような化合物を含有する組成物、及び使用方法
AU2003291959A1 (en) 2002-12-20 2004-07-14 Novo Nordisk A/S Novel glucagon antagonists
US20040209928A1 (en) 2002-12-30 2004-10-21 Ravi Kurukulasuriya Glucagon receptor antagonists/inverse agonists
US7151114B2 (en) 2003-01-09 2006-12-19 Boehringer Ingelheim International Gmbh Use of substituted 2-phenylbenzimidazoles as medicaments
DE10300398A1 (de) 2003-01-09 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel
WO2004063147A1 (en) 2003-01-10 2004-07-29 Novo Nordisk A/S Salts and solvates of glucagon antagonists
EP1590336B1 (en) 2003-01-27 2010-12-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
WO2004092146A2 (en) 2003-04-14 2004-10-28 The Institutes For Pharmaceutical Discovery, Llc N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
US7138529B2 (en) 2003-04-16 2006-11-21 Hoffmann-La Roche Inc. Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
EA200501713A1 (ru) 2003-04-30 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Фенилзамещённые карбоновые кислоты
JP2006528687A (ja) 2003-05-09 2006-12-21 メルク　エンド　カムパニー　インコーポレーテッド ベンズイミダゾール、こうした化合物を含有する組成物および使用方法
US7355049B2 (en) 2003-06-24 2008-04-08 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activator
JP4412098B2 (ja) 2003-07-31 2010-02-10 Ｊｆｅスチール株式会社 溶接熱影響部靭性に優れた低降伏比高強度鋼板及びその製造方法
US7459472B2 (en) 2003-08-08 2008-12-02 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
JP2007514794A (ja) 2003-12-19 2007-06-07 メルク　エンド　カムパニー　インコーポレーテッド 環式グアニジン、そのような化合物を含む組成、及び使用方法
WO2005058845A2 (en) 2003-12-19 2005-06-30 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ
ES2428538T3 (es) * 2004-05-28 2013-11-08 Eli Lilly And Company Antagonistas del receptor de glucagón, preparación y usos terapéuticos
GEP20094605B (en) 2004-06-04 2009-02-10 Merck & Co Inc Pyrazole derivatives, compositions containing such compounds and methods of use thereof
DK1758853T3 (da) 2004-06-14 2010-04-06 Lilly Co Eli Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
CA2572745A1 (en) 2004-07-07 2006-02-16 Teresa Beeson Pyrazole amide derivatives, compositions containing such compounds and methods of use
AU2005269792B9 (en) 2004-07-22 2008-11-27 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
DE102004051188A1 (de) 2004-10-21 2006-04-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cyanothiophene, deren Herstellung und deren Verwendung als Arzneimittel
US7524870B2 (en) 2004-12-03 2009-04-28 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
ATE445609T1 (de) 2005-02-11 2009-10-15 Lilly Co Eli Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
CA2600159A1 (en) 2005-03-21 2006-09-28 Merck & Co., Inc. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
CA2600833A1 (en) 2005-03-30 2006-10-05 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7709658B2 (en) 2005-07-26 2010-05-04 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
DK1951272T3 (en) 2005-10-06 2016-09-19 Probi Ab Use of lactobacillus for treatment of virus infections
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
AR056574A1 (es) 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
EP1959958A4 (en) 2005-11-14 2010-07-14 Univ Southern California INTEGRIN-BINDING SMALL MOLECULES
CA2629348C (en) * 2005-11-17 2013-08-13 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
DK1951658T3 (da) * 2005-11-17 2012-10-15 Lilly Co Eli Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser
BRPI0618484A2 (pt) * 2005-11-18 2011-08-30 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de glucagon em um mamìfero, para reduzir seletivamente o nìvel glicêmico em um mamìfero e para tratar diabete tipo 2, e, uso de um composto ou um sal do mesmo
WO2007120270A2 (en) * 2005-11-22 2007-10-25 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
US7807702B2 (en) 2005-11-23 2010-10-05 Eli Lilly And Company Substituted thiophene carboxylic amide glucagon receptor antagonists, preparation and therapeutic uses
CA2633010A1 (en) 2005-12-19 2007-06-28 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
TW200806611A (en) 2006-02-09 2008-02-01 Daiichi Seiyaku Co Novel amidopropionic acid derivatives and medicine containing the same
CA2645639A1 (en) 2006-03-23 2007-10-04 Merck & Co. Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2019585A2 (en) 2006-05-16 2009-02-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20170085615A (ko) 2007-02-09 2017-07-24 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
JP2009040702A (ja) 2007-08-07 2009-02-26 Daiichi Sankyo Co Ltd 新規アミドプロピオン酸誘導体を含有する医薬組成物
US8232413B2 (en) 2007-09-12 2012-07-31 Merck Sharp & Dohme Corp. Process for the production of a crystalline glucagon receptor antagonist compound
WO2009057784A1 (ja) 2007-11-01 2009-05-07 Takeda Pharmaceutical Company Limited 複素環化合物
CA2707448C (en) 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
KR101616140B1 (ko) 2008-03-05 2016-04-27 다케다 야쿠힌 고교 가부시키가이샤 복소환 화합물
EP2262364B1 (en) 2008-03-07 2016-03-02 vTv Therapeutics LLC Oxadiazoanthracene compounds for the treatment of diabetes
JP2011520897A (ja) 2008-05-16 2011-07-21 シェーリング コーポレイション グルカゴン受容体アンタゴニスト、組成物およびそれらの使用方法
EP2799428B1 (en) 2008-08-13 2016-11-16 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2010019828A1 (en) 2008-08-13 2010-02-18 Metabasis Therapeutics, Inc. Glucagon receptor antagonists
WO2010030722A1 (en) 2008-09-15 2010-03-18 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AR073412A1 (es) 2008-10-03 2010-11-03 Schering Corp Derivados de espiro imidazolona como antagonistas del receptor glucagon y composiciones que los comprende.
WO2010071750A1 (en) 2008-12-19 2010-06-24 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds
US8697740B2 (en) 2009-01-12 2014-04-15 Merck Sharp & Dohme Corp. Crystalline polymorphic forms of an antidiabetic compound
WO2010088061A1 (en) 2009-01-28 2010-08-05 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010098948A1 (en) 2009-02-13 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containin such compounds and methods of use
WO2010098994A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8883824B2 (en) 2009-05-14 2014-11-11 Sumitomo Dainippon Pharma Co., Ltd. 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof
US8470773B2 (en) 2009-06-12 2013-06-25 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
JP2012188352A (ja) 2009-07-13 2012-10-04 Dainippon Sumitomo Pharma Co Ltd ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩
WO2011027849A1 (ja) 2009-09-04 2011-03-10 武田薬品工業株式会社 複素環化合物
WO2011037815A1 (en) 2009-09-22 2011-03-31 Schering Corporation Novel pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
AU2011232675A1 (en) 2010-03-25 2012-09-27 Merck Sharp & Dohme Corp. Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use
AU2011232657A1 (en) 2010-03-26 2012-09-27 Merck Sharp & Dohme Corp. Novel spiro imidazolone derivatives as glucagon receptor antagonists, compositions, and methods for their use
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
WO2012107850A1 (en) * 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator

Also Published As

Publication number Publication date
CR20130372A (es) 2013-09-18
CO6741217A2 (es) 2013-08-30
TW201429947A (zh) 2014-08-01
KR101585840B1 (ko) 2016-01-15
KR101638671B1 (ko) 2016-07-11
CA2825102A1 (en) 2012-08-16
AU2012215114B2 (en) 2016-05-12
TW201245146A (en) 2012-11-16
US20130296355A1 (en) 2013-11-07
CN104744370A (zh) 2015-07-01
US8507533B2 (en) 2013-08-13
PE20140253A1 (es) 2014-03-09
CN103370306B (zh) 2015-12-02
NZ613269A (en) 2014-06-27
ECSP13012871A (es) 2013-10-31
GEP20156351B (en) 2015-08-25
ZA201306310B (en) 2014-04-30
US20120202834A1 (en) 2012-08-09
PH12013501557A1 (en) 2019-06-03
CY1118039T1 (el) 2017-05-17
RS55225B1 (sr) 2017-02-28
AR085149A1 (es) 2013-09-11
BR112013020035A2 (pt) 2016-07-19
US20150266859A1 (en) 2015-09-24
UY33896A (es) 2012-09-28
ME02502B (me) 2017-02-20
ES2597972T3 (es) 2017-01-24
NI201300068A (es) 2013-12-11
US9452999B2 (en) 2016-09-27
MX2013009140A (es) 2013-10-01
IL227559A0 (en) 2013-09-30
EA201390969A1 (ru) 2013-12-30
JP5562495B2 (ja) 2014-07-30
US8859591B2 (en) 2014-10-14
KR20150038705A (ko) 2015-04-08
EP2673260B1 (en) 2016-08-17
LT2673260T (lt) 2016-10-25
JP2014504631A (ja) 2014-02-24
DOP2013000181A (es) 2013-09-30
US9073871B2 (en) 2015-07-07
EP2673260A1 (en) 2013-12-18
CA2825102C (en) 2016-03-08
IL227559A (en) 2016-04-21
US20140371467A1 (en) 2014-12-18
US20160362392A1 (en) 2016-12-15
AP2013007012A0 (en) 2013-07-31
AP3338A (en) 2015-07-31
HUE030364T2 (hu) 2017-04-28
PT2673260T (pt) 2016-10-24
HK1207858A1 (en) 2016-02-12
TW201540710A (zh) 2015-11-01
WO2012107850A1 (en) 2012-08-16
HRP20161177T1 (hr) 2016-11-04
AU2012215114A1 (en) 2013-08-01
SI2673260T1 (sl) 2016-10-28
HK1188992A1 (zh) 2014-05-23
EA023517B1 (ru) 2016-06-30
SG192004A1 (en) 2013-08-30
CL2013002053A1 (es) 2013-11-29
KR20130118385A (ko) 2013-10-29
CN103370306A (zh) 2013-10-23
DK2673260T3 (en) 2016-10-10
TWI490202B (zh) 2015-07-01

Similar Documents

Publication Publication Date Title
GT201300196A (es) Moduladores del receptor de glucagón
DOP2013000307A (es) Antagonistas de trpv4
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
EA201591748A1 (ru) Модуляторы p2x7
UY37410A (es) Antagonistas de trpv4
CR20120542A (es) HETEROARIL-CICLOHEXIL-TETRAAZABENZO [e] AZULENOS
DOP2014000075A (es) Moduladores selectivos del receptor andrógeno
CL2013000733A1 (es) Compuestos derivados de arilalquilimidazol, moduladores selectivos de receptores alfa 2 adrenergicos; y composicion farmaceutica que los comprende.
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
MX2016000219A (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
CL2015000359A1 (es) Compuestos derivados de pirrolopirazoles sustituidos, bloqueadores del canal de calcio tipo n; y composicion farmaceutica que los comprende.
CO7240378A2 (es) Indolcarbonitrilos como moduladores selectivos de los receptores de andrógeno
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
UY32520A (es) Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
BR112016027133A8 (pt) derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
MX365438B (es) Compuestos de tipo 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores mglur2.
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
UY34595A (es) Composición farmacéutica de liberación prolongada de trimetazidina
UY33409A (es) Moduladores no competitivos de receptores nicotinicos
MX2019002166A (es) Agonistas del receptor cxcr3.